Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder

Medical University of South Carolina (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for tobacco use disorder when delivered in conjunction with brief motivational enhancement therapy. Participants will receive ketamine assisted motivational enhancement therapy weekly for three weeks and there will be 2 follow up visits. All visits will also consist of questionnaires and saliva samples will be taken. The overall participation will last approximately 8 weeks.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ketamine Hydrochloride
  • Behavioral: Motivational enhancement therapy
Early Phase 1

Study Design

Study Type:
Anticipated Enrollment :
8 participants
Intervention Model:
Single Group Assignment
Intervention Model Description:
Pilot StudyPilot Study
None (Open Label)
Primary Purpose:
Official Title:
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment of tobacco use disorder with ketamine

Drug: Ketamine Hydrochloride
IM ketamine given in weekly session for a total of 3 weeks

Behavioral: Motivational enhancement therapy
Brief motivational based therapy

Outcome Measures

Primary Outcome Measures

  1. Feasibility of ketamine treatment for tobacco use disorder [8 weeks]

    The primary outcome of this study will be the feasibility of using ketamine-assisted treatment for smoking cessation, which will assess the number of people selected for randomization that complete the full treatment. This will help determine if the treatment of ketamine in tobacco use would be beneficial for further study.

Secondary Outcome Measures

  1. Smoking cessation [Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8]

    Saliva cotinine levels will be collected prior to each ketamine session and at each follow up to detect smoking over approximately the past 6 days

  2. Reduction in cigarettes smoked per day [Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8]

    Evaluate if there is reduction in cigarettes smoked per day via the self-reported time-line follow back

Eligibility Criteria


Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. 21 to 65 years old.

  2. Able to provide informed consent.

  3. Be a daily cigarette smoker with multiple unsuccessful previous quit attempts, and report a continued desire to quit smoking.

  4. Agree to abstain from smoking for the ketamine session from 1 hour before ketamine administration

  5. Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of ketamine administration. Exceptions include caffeine and nicotine.

  6. Subjects taking other psychotropic medications must be maintained on a stable dose for at least four weeks before study initiation.

  7. Be healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG) to verify normal QTc intervals.

  8. Subjects with normal blood pressure not on antihypertensive medications or medication controlled hypertension as defined baseline visit systolic blood pressure (SBP) <140 mmHg or a diastolic blood pressure (DBP) <90 mmHg.

Exclusion Criteria:
  1. Women who are pregnant (positive pregnancy test) or nursing, or are not practicing an effective means of birth control which can include oral, implant, intrauterine device, or patch contraceptive methods as well as barrier contraceptive methods, history of surgery such as hysterectomy or tubal ligation, or abstinence

  2. Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders or current depression or bipolar disorder based on clinical interview.

  3. Subjects meeting DSM-5 criteria for current substance use disorder other than tobacco use disorder.

  4. Subjects with hypertension as defined by a baseline visit systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) >90 mmHg.

  5. A history of allergic or other adverse reaction to ketamine (or its excipients).

  6. Clinically significant physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma, aneurysmal disease, cardiovascular disease, or end-stage renal disease).

  7. Cardiovascular conditions: uncontrolled hypertension, angina, a clinically significant ECG abnormality (e.g., atrial fibrillation), TIA in the last 6 months, stroke, peripheral or pulmonary vascular disease

  8. Subjects who live greater than 20 miles from the study site and cannot arrange their own transportation will be excluded from the study.

  9. Subjects with clinically significant kidney or liver impairment.

  10. Have any current neurological illnesses including, but not limited to, seizure disorders, frequent migraines or on prophylaxis, multiple sclerosis, movement disorders, history of significant head trauma, or CNS tumor.

  11. Morbidly obese (BMI >40), or severely underweight as determined by medical examination.

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Medical University of South Carolina


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Emily Amador, Medical/Dental Resident, Medical University of South Carolina Identifier:
Other Study ID Numbers:
  • Pro00126022
First Posted:
Apr 4, 2023
Last Update Posted:
Apr 4, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2023